Androgens, Growth Factors, and Ovarian Cancer

雄激素、生长因子和卵巢癌

• 批准号: 6654882
• 负责人: KATHY J HELZLSOUER
• 金额: $ 7.45万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-04 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6654882
• 关键词: androgens; androstenedione; binding proteins; cancer risk; clinical research; dehydroepiandrosterone; disease /disorder etiology; female; hormone related neoplasm /cancer; human subject; insulinlike growth factor; ovary neoplasms; patient oriented research; serology /serodiagnosis; testosterone

DESCRIPTION (provided by applicant)Evidence and theoretical considerations point towards hormonal mechanisms in ovarian carcinogenesis. Because of the widespread use of hormones for prevention and treatment of wide variety of diseases (e.g. cancer, cardiovascular disease and osteoporosis) it is critical to understand the effects of hormones on the development of ovarian cancer in order to predict the safety of hormone interventions and to develop new methods of prevention. We hypothesize that androgens and insulin-like growth factor, are associated with the development of ovarian cancer and could be potential targets for prevention interventions. A prospective study will be conducted using the efficiency of a nested case control design, to evaluate the association between circulating components of the insulin growth factor (IGF) axis, endogenous androgens and the subsequent development of ovarian cancer. Cases and controls will be selected from the Washington County, MD cohort studies, CLUE I and CLUE II. All participants have blood available prior to the time of diagnosis of cancer. 86 women from these cohorts have developed ovarian cancer and are eligible for the study. Each case will be matched to two controls by age, race, cohort participation, menstrual status (including time since last menstrual period), and date of blood draw. This study will contribute to the understanding of the etiology of ovarian cancer. Designs of future hormonal chemopreventive intervention need to be based on a clearer understanding of the hormonal influences underlying cancer so that potential risks and benefits of existing and new interventions can be determined.

描述(由申请人提供)证据和理论考虑指向卵巢癌发生的激素机制。由于激素被广泛用于预防和治疗多种疾病(如癌症、心血管疾病和骨质疏松症)，因此了解激素在卵巢癌发展中的作用，以预测激素干预的安全性和开发新的预防方法是至关重要的。我们假设雄激素和胰岛素样生长因子与卵巢癌的发生有关，并可能成为预防干预的潜在靶点。一项前瞻性研究将使用嵌套病例对照设计的效率，以评估胰岛素生长因子(IGF)轴的循环成分、内源性雄激素与卵巢癌后续发展之间的关系。 病例和对照将从华盛顿县，MD队列研究，线索I和线索II中挑选出来。所有参与者在被诊断为癌症之前都有可用的血液。这些队列中的86名女性患上了卵巢癌，有资格参加这项研究。每个病例将根据年龄、种族、队列参与、月经状况(包括自上次月经以来的时间)和抽血日期与两个对照配对。 这项研究将有助于了解卵巢癌的病因。未来荷尔蒙化学预防干预的设计需要更清楚地了解癌症背后的荷尔蒙影响，以便能够确定现有和新干预措施的潜在风险和好处。